|
 |
AndroGelThis page contains recent news articles, when available, and an overview of AndroGel but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: AndroGel (when available) Testosterone is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Testosterone is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Testosterone blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration. For topical testosterone replacement therapy in males with deficiency or absence of testosterone Mechanism Of Action: Testosterone competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. News Articles on Testosterone Testosterone therapy to be put to the test - Dec 12, 2009 Prescriptions soared from 648000 in 1999 to 3.3 million last year, fueled by the 2000 approval of Solvay Pharmaceuticals' AndroGel, the first rub-on ... Seattle Times 2 Belgian drug companies in metro Atlanta have different futures - Dec 10, 2009 Some of Solvay's main products are AndroGel, a testosterone replacement therapy; Aceon, a treatment for patients with essential hypertension; and Estratest, ... Atlanta Journal Constitution Doctor accused of negligence is reprimanded by state medical board - Dec 9, 2009 In September, the patient saw Knorr before moving to Santa Rosa to be near his son and was prescribed Androgel, which contains testosterone, ... Santa Cruz Sentinel Watson Announces New Program to Help Promote Good Bone Health in Advanced ... - Dec 14, 2009 In addition, Watson markets the following brands under co-promotion agreements: AndroGel®, with Solvay Pharmaceuticals, Inc., and Femring®, ... CNNMoney.com (press release) New Published Data Demonstrate Long-Term Safety, Efficacy and Tolerability of ... - Dec 9, 2009 In addition, Watson markets the following brands under co-promotion agreements: AndroGel®, with Solvay Pharmaceuticals, Inc., and Femring®, ... CNNMoney.com (press release) Endo Pharma Gets a Setback - Dec 11, 2009 Once launched, Fortesta and Aveed will compete with Auxilium Pharma's (AUXLt) Testim and Solvay Pharmaceuticals' AndroGel. Seeking Alpha (blog) Repros Therapeutics Announces Settlement with Major Creditors - Oct 30, 2009 Previously Repros showed Androxal to be non inferior to Androgel when comparing circulating testosterone levels. Androgel is a topical testosterone gel and ... Reuters FTC, drugstores sue Solvay over delay in generic AndroGel - Oct 24, 2009 AndroGel, marketed as a treatment for men with low testosterone levels, rang up more than $400 million in global sales last year. ... Atlanta Business Chronicle Low sex drive? Testosterone gel could help -- or not - Nov 2, 2009 Solvay Pharmaceuticals posted nearly $500 million in global sales of AndroGel last year for the treatment of low testosterone, which has been branded as ... Pioneer Press Watson Pharmaceuticals Q3 net income down - Nov 6, 2009 ...exceeded $112 million, the result of contributions from new products such as Rapaflo and Gelnique, and promoted products such as AndroGel and Femring." American Chronicle Watson Reports Third Quarter 2009 GAAP EPS of $0.55; Adjusted EPS of $0.66 - Nov 4, 2009 Brand other revenue increased $4.9 million to $16.6 million, due primarily to increased revenue from the Company's promotion of AndroGel® and Femring®. ... Reuters Testosterone Is Sure Looking Virile - Oct 30, 2009 28 drug giant Abbott Laboratories (ABT) paid $6.6 billion to acquire Solvay Pharmaceuticals, which makes the leading testosterone product, AndroGel. ... BusinessWeek US Court of Appeals Enforces Subpoenas in FTC's Androgel Investigation; In ... - Oct 28, 2009 ...“We were gratified to see the DC Circuit act so quickly on this appeal in Androgel,â€? said Richard Feinstein, Director of the FTC's Bureau of Competition. ... 7thSpace Interactive (press release) Areva, Nokia, Roche, Solvay, Telenet: European Equity Preview - Oct 25, 2009 ...makers must comply with a subpoena in a probe into whether they colluded to delay lower-cost copies of the company's Androgel testosterone treatment. ... Bloomberg Watson Pharma Beats by a Penny - Nov 4, 2009 Other revenues in the brand segment increased 41.9% to $16.6 million, thanks to increased revenue from the company's promotion of AndroGel and Femring. ... Zacks.com Pharma Execs' Subpoena Argument Falls Flat - Oct 27, 2009 Laboratories Besins Iscovesco, and Solvay Pharmaceuticals delayed entry of a lower cost generic version of a testosterone drug called AndroGel. ... Courthouse News Service Drug Industry Executives Try to Weasel Out of Testifying - Oct 30, 2009 ...and Solvay Pharmaceuticals—are accused of conspiring to keep a generic version of the testosterone drug AndroGel from becoming available on the market. ... AllGov SOLVAY : Operating result in the third quarter (EUR 285 million) in line with ... - Oct 28, 2009 They benefited from the sustained growth of certain drugs such as Androgel® (EUR +88 million), Creon® (EUR +35 million) and Influvac® (EUR +34 million), ... ITnews.it Solvay boekt hogere nettowinst dankzij afdeling die de deur uit moet - Oct 29, 2009 De farmadivisie zette 8 procent meer om, dankzij de goede verkoop van geneesmiddelen als Androgel, Creon en Influvac, maar ook dankzij gunstige ... De Tijd Reazioni avverse per i bambini esposti casualmente al gel a base di Testosterone - Oct 28, 2009 L'FDA ( Food and Drug Administration ) ha informato i medici che farà inserire nella scheda tecnica di 2 prodotti topici ( gel ) di Testosterone, AndroGel ... XagenaSalute Omzet Solvay onder druk moeilijke marktomstandigheden - Oct 29, 2009 In de farmadivisie werd een omzetgroei van 8 % opgetekend, dankzij de uitstekende verkoop van geneesmiddelen zoals Androgel, Creon en Influvac, ... Express.be å?‹è?¯ç”ŸæŠ€å‰?三å£EPS2.68å…ƒ - Oct 31, 2009 ...西藥處的高血壓用藥Zanidipã€?男性賀爾蒙擦劑Androgelã€?以å?Šç³–尿病複方藥å“?GlucoMet ç‰ç”¢å“?銷售穩定地æŒ?續æˆ?長，與去年å?ŒæœŸç›¸æ¯”營收ä»?æˆ?長將近17%。 ... eTaiwan News Operationeel resultaat voor het 3e kwartaal (285 miljoen EUR) ligt in de lijn ... - Oct 28, 2009 Dit is te danken aan de aanhoudende groei van bepaalde geneesmiddelen zoals Androgel® (+88 miljoen EUR), Creon® (+35 miljoen EUR) en Influvac® (+34 miljoen ... Euronext (persbericht) Biotechbedrijf Pronota realiseert kapitaalverhoging van € 1,3 miljoen - Nov 1, 2009 In de farmadivisie werd een omzetgroei van 8 % opgetekend, dankzij de uitstekende verkoop van geneesmiddelen zoals Androgel, Creon en Influvac, ... Express.be IBA gaat apparatuur voor protontherapie verhuren - Oct 30, 2009 In de farmadivisie werd een omzetgroei van 8 % opgetekend, dankzij de uitstekende verkoop van geneesmiddelen zoals Androgel, Creon en Influvac, ... Express.be Vakbonden UCB vrezen voor collectief ontslag - Oct 28, 2009 In de farmadivisie werd een omzetgroei van 8 % opgetekend, dankzij de uitstekende verkoop van geneesmiddelen zoals Androgel, Creon en Influvac, ... Express.be Résultat opérationnel au 3ème trimestre (285 millions EUR) - Oct 28, 2009 Ilbénéficie de la croissance soutenue de certains médicaments tels qu'Androgel® (+88 millions EUR), Creon® (+35 millions EUR) et Influvac® (+34 millions ... EasyBourse.com Brand Names/Synonyms: AndroGel is also known by the following brand names and/or synonymsAA 2500; Andriol; Andro; Andro 100; Andro L.A. 200; Androderm; Androgel; Android 10; Android 25; Android 5; Androlin; Andronaq; Andronate 100; Andronate 200; Andropatch; Andropository 200; Andrusol; Andryl 200; Beta Testosterone; CCRIS 574; CDB 111C; COL 1621; CP 601B; Cristerona T; Cristerone T; Dea No. 4000; Delatest; Delatestryl; Depo-Testosterone; Depo-Testosterone Cypionate; Depotest; Dofsol; Everone 200; Geno-Cristaux Gremy; HSDB 3398; Homosteron; Homosterone; Libigel; Malerone; Malestrone; Malogen in Oil; Malogen, Aquaspension Injection; Mertestate; Metandren; Methyltestosterone; NSC 9700; Neo-Hombreol F; Neo-Testis; Neotestis; Oreton; Oreton F; Oreton Methyl; Oreton-F; Orquisteron; Perandren; Percutacrine Androgenique; Primotest; Primoteston; Relibra; Scheinpharm Testone-Cyp; Striant; Sustanon; Sustanone; Sustason 250; Synandrol F; T-Cypionate; TES; Teslen; Testamone 100; Testandrone; Testaqua; Testex; Testiculosterone; Testim; Testobase; Testoderm; Testoderm Tts; Testogel; Testoject-50; Testolin; Testopel Pellets; Testopropon; Testosteroid; Testosteron; Testosterona [Inn-Spanish]; Testosterone; Testosterone Cypionate; Testosterone Enanthate; Testosterone Hydrate; Testosterone Propionate; Testosterone [Ban:Inn]; Testosterone and Its Esters; Testosteronum [Inn-Latin]; Testostosterone; Testoviron; Testoviron Schering; Testoviron T; Testred; Testred Cypionate 200; Testrin-P.A; Testro Aq; Testrone; Testryl; Trans-Testosterone; Virilon; Virilon Im; Virormone; Virosterone Drug Category: AndroGel is categorized under the following by the FDA: Antineoplastic Agents; Anabolic Agents; Androgens; ATC:G03BA02; ATC:G03BA03; ATC:G03EK01 Dosage Forms: CAPSULE; GEL; LIQUID; PATCH; SOLUTION; SUSPENSION Absorption: Approximately 10% of the testosterone dose applied on the skin surface from AndroGel® is absorbed into systemic circulation Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
